Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in patients awaiting kidney transplantation
2019-004154-28Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of isatuximab in end-stage kidney disease (ESKD), sponsored by Sanofi. Primary endpoints: Phase 1 safety and tolerability (AEs/SAEs and laboratory abnormalities) and Phase 2 safety profile of isatuximab. Started Dec 2019; status: terminated.
02
Drugs
isatuximab
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2019-004154-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004154-28.